PLYX Polaryx Therapeutics, Inc. - Common Stock
$3.14
Price · May 20, 2026
Fundamentals as of May 15, 2026
52W Range
$2–$49
2% of range
Analyst Rating
BUY
7 analysts
Price Target
$10
+218% upside
P/E (TTM)
—
ROE
-193.7%
Net Profit Margin
—
PLYX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$3.14
Market Cap
—
P/E (TTM)
—
EPS (TTM)
$-0.20
Revenue (TTM)
—
Div Yield
—
ROE
-193.7%
Debt/Equity
—
52W Range
$2 – $49
PLYX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
$-0.20
2024-12-31
→
2025-12-31
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
PLYX
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
PLYX
Peer Median
ROA
-176.7%
—
ROE
-193.7%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
PLYX
Peer Median
Current Ratio
8.5
—
Quick Ratio
8.5
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
PLYX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
PLYX
Peer Median
PLYX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-05-15
Low
$10.00
High
$10.00
Median target
$10.00
+218.5%
Mean target
$10.00
+218.5%
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| PLYX | — | — | — | — | -193.7% | — |
| CNTX | $135M | -3.9 | 112.7% | — | -50.5% | — |
| ORMP | $112M | 1.9 | -50.4% | 3202.5% | 37.0% | 0.65% |
| DERM | — | -16.4 | 10.2% | -18.5% | -44.7% | — |
| ANTX | $31M | -1.0 | — | — | -57.7% | — |
| ASRT | $58M | -1.9 | -5.0% | -25.6% | -32.4% | — |
| NTHI | — | -2.6 | -51.8% | — | — | — |
| TTRX | $116M | -32.8 | — | — | -141.7% | — |
| RANI | — | -3.0 | 58.9% | -1817.1% | -169.6% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 11
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | $6M | $3M | |
| SG&A Expense | $2M | $2M | |
| Operating Expenses | $8M | $4M | |
| Operating Income | $-8M | $-4M | |
| Pretax Income | $-9M | $-30M | |
| Net Income | $-9M | $-30M | |
| EPS (Basic) | $-0.20 | $-0.89 | |
| EPS (Diluted) | $-0.20 | $-0.89 | |
| Shares (Basic) | 45,422,581 | 34,200,660 | |
| Shares (Diluted) | 45,422,581 | 34,200,660 | |
| EBITDA | $-8M | · |
Balance Sheet 15
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $5M | $5M | |
| Prepaid Expense | · | $380.0K | |
| Other Current Assets | $27.0K | · | |
| Current Assets | $5M | $5M | |
| Total Assets | $5M | $5M | |
| Accounts Payable | $470.0K | $72.0K | |
| Accrued Liabilities | $23.0K | · | |
| Current Liabilities | $605.0K | $289.0K | |
| Total Liabilities | $605.0K | $289.0K | |
| Common Stock | $5.0K | $4.0K | |
| Paid-in Capital | $104M | $95M | |
| Retained Earnings | $-100M | $-91M | |
| Stockholders' Equity | $5M | $5M | |
| Liabilities + Equity | $5M | $5M | |
| Shares Outstanding | 47,343,297 | 41,151,571 |
Cash Flow 5
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Stock-based Comp | $5M | $2M | |
| Operating Cash Flow | $-4M | $-3M | |
| Stock Issued | $4M | $7M | |
| Net Stock Activity | $4M | · | |
| Financing Cash Flow | $4M | $7M |
Profitability 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -176.7% | · | |
| ROE | -193.7% | · |
Liquidity & Solvency 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 8.5 | · | |
| Quick Ratio | 8.5 | · |
Valuation (TTM) 1
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-9M | · |
Income Statement 10
| Metric | Trend | Q1 2026 |
|---|---|---|
| R&D Expense | $679.0K | |
| SG&A Expense | $1M | |
| Operating Expenses | $2M | |
| Operating Income | $-2M | |
| Net Income | $-3M | |
| EPS (Basic) | $-0.05 | |
| EPS (Diluted) | $-0.05 | |
| Shares (Basic) | 47,219,329 | |
| Shares (Diluted) | 47,219,329 | |
| EBITDA | $-2M |
Balance Sheet 15
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cash & Equivalents | $3M | |
| Prepaid Expense | $389.0K | |
| Other Current Assets | $33.0K | |
| Current Assets | $4M | |
| Total Assets | $4M | |
| Accounts Payable | $850.0K | |
| Accrued Liabilities | $45.0K | |
| Current Liabilities | $1M | |
| Total Liabilities | $1M | |
| Common Stock | $5.0K | |
| Paid-in Capital | $105M | |
| Retained Earnings | $-102M | |
| Stockholders' Equity | $2M | |
| Liabilities + Equity | $4M | |
| Shares Outstanding | 47,343,297 |
Cash Flow 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| Stock-based Comp | $467.0K | |
| Operating Cash Flow | $-2M |
Profitability 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -145.3% | |
| ROE | -204.5% |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 3.5 | |
| Quick Ratio | 3.0 |
Valuation (TTM) 4
| Metric | Trend | Q1 2026 |
|---|---|---|
| Market Cap | $358M | |
| P/B | 143.9 | |
| P / Tangible Book | 143.9 | |
| P / Cash Flow | -173.5 |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $-9M | $-30M |
| Diluted EPS | $-0.20 | $-0.89 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Current Ratio | 8.5 | — |
| Quick Ratio | 8.5 | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.